Depigmented patches covering approximately 15% of newborn's body, surrounded by areas of thickened skin. Mild scaling and hyperpigmentation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the serum level of Lipocalin 2 in vitiligo.
Arch Dermatol Res
January 2025
Department of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Vitiligo is considered as depigmenting skin disorder where patches of skin losing their pigment. Lipocalin-2 (LCN2) is one of the Inflammatory adipokines that has a potential role in skin disorders and other inflammatory diseases as well. To measure the concentration level of LCN2 in vitiligo patients compared to healthy controls and to investigate its relation to disease activity and other clinical data to evaluate its role in the pathogenesis of the disease.
View Article and Find Full Text PDFFractional CO laser combined with narrow-band ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in vitiligo patients: prospective, self-controlled, and randomized trial.
Lasers Med Sci
January 2025
Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Vitiligo is a chronic depigmenting condition that causes amelanotic macules and patches on the skin. Despite various treatment options, treating vitiligo is a challenge. This study aimed to evaluate the combination of laser CO fractional and narrow-band ultraviolet B (NB-UVB) versus NB-UVB monotherapy in vitiligo patients.
View Article and Find Full Text PDFRole of miR-16, 146a, 19b and 720 gene expressions in the pathogenesis and diagnosis of vitiligo.
Sci Rep
January 2025
Department of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Vitiligo is a common long-term depigmenting skin disorder that is characterized by patches of skin losing their pigment. To evaluate serum/tissue levels of miR-16, 146a, 19b and 720 in vitiligo patients and healthy controls, also analyzing the correlations between all biomarkers to indicate whether those can be used to early diagnose vitiligo patients. Forty-subjects were included, divided into two equal groups, 20 healthy matched individuals and 20 vitiligo patients.
View Article and Find Full Text PDFCombination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Background: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).
View Article and Find Full Text PDFLichen Planus Pigmentosus and Vitiligo in a 61-Year-Old Filipino Man: Case Report.
JMIR Dermatol
November 2024
Department of Dermatology, De La Salle Medical and Health Sciences Institute, Dasmariñas, Cavite, Philippines.
Article Synopsis
- - Pigmentary disorders like Lichen planus pigmentosus (LPP) and vitiligo can lead to significant cosmetic concerns and psychosocial stress for patients.
- - A 61-year-old man with LPP developed vitiligo and was successfully treated with low-dose isotretinoin and topical tacrolimus ointment.
- - The coexistence of LPP and vitiligo might be explained by an autoimmune process affecting skin pigmentation called melanocytorrhagy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!